ArticleJHLT open2023
Pulmonary alveolar proteinosis postlung transplantation: A causation conundrum.
Article in JHLT open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lung transplantation for pulmonary alveolar proteinosis: a retrospective international multicentre analysis.The European respiratory journal · 2026Article
- The dark side of pulmonary alveolar proteinosis.Multidisciplinary respiratory medicine · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary alveolar proteinosis (PAP) is a rare pulmonary disorder caused by defective granulocyte-macrophage colony-stimulating factor signaling, leading to abnormalities of macrophage metabolic and immune functions, with resultant impaired surfactant metabolism and its accumulation within the alveoli. PAP can relapse in patients who underwent lung transplantation for PAP related to genetic defects. However, its occurrence is exceedingly rare in lung allografts of patients who underwent lung transplantation for other primary end-stage lung disease. Prompt diagnosis and appropriate treatment strategy are crucial to prevent the decline in the allograft function and to avoid unnecessary empiric treatments for rejection and/ infection. Here we present a case of PAP in a patient, 8 months postbilateral lung transplantation for COVID-19 fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.